Literature DB >> 11257347

The incurable wound revisited: progress in human rabies prevention?

C A Hanlon1, M Niezgoda, P A Morrill, C E Rupprecht.   

Abstract

Rabies is the most important viral zoonosis from a global perspective. Modern human postexposure prophylaxis consists of potent vaccines and local infiltration of rabies immune globulins (RIGs), but the latter biologicals are not widely available or affordable. Monoclonal antibodies (Mabs) offer several theoretical advantages over RIGs. To this end, several human and equine RIGS, alone or in combination with vaccine, were investigated for postexposure efficacy in a Syrian hamster model, compared with a single neutralizing murine Mab. Preliminary results suggest that: (1) animal models continue to provide utility as human surrogates in the demonstration of product efficacy against rabies; (2) RIG preparations differ substantially in experimental effectiveness and clearance; and (3) relevant alternatives, such as Mabs, should be pursued for future improvements to human rabies prevention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257347     DOI: 10.1016/s0264-410x(00)00516-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.

Authors:  Alexander B H Bakker; Wilfred E Marissen; R Arjen Kramer; Amy B Rice; William C Weldon; Michael Niezgoda; Cathleen A Hanlon; Sandra Thijsse; Harold H J Backus; John de Kruif; Bernhard Dietzschold; Charles E Rupprecht; Jaap Goudsmit
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Injecting rabies immunoglobulin (RIG) into wounds only: A significant saving of lives and costly RIG.

Authors:  Omesh Kumar Bharti; Shampur Narayan Madhusudana; Henry Wilde
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

Review 3.  Time to Revise the WHO Categories for Severe Rabies Virus Exposures-Category IV?

Authors:  Stephen J Scholand; Beatriz P Quiambao; Charles E Rupprecht
Journal:  Viruses       Date:  2022-05-22       Impact factor: 5.818

4.  Public health surveillance for Australian bat lyssavirus in Queensland, Australia, 2000-2001.

Authors:  David Warrilow; Bruce Harrower; Ina L Smith; Hume Field; Roscoe Taylor; Craig Walker; Greg A Smith
Journal:  Emerg Infect Dis       Date:  2003-02       Impact factor: 6.883

5.  Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice.

Authors:  Sanne Terryn; Aurélie Francart; Sophie Lamoral; Anna Hultberg; Heidi Rommelaere; Angela Wittelsberger; Filip Callewaert; Thomas Stohr; Kris Meerschaert; Ingrid Ottevaere; Catelijne Stortelers; Peter Vanlandschoot; Michael Kalai; Steven Van Gucht
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

Review 6.  Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its Cure.

Authors:  Arnaud Tarantola
Journal:  Trop Med Infect Dis       Date:  2017-03-24

7.  In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity.

Authors:  Waranyoo Phoolcharoen; Ashley C Banyard; Christophe Prehaud; David Selden; Guanghui Wu; Colin P D Birch; Tim H Szeto; Monique Lafon; Anthony R Fooks; Julian K-C Ma
Journal:  Vaccine       Date:  2018-03-06       Impact factor: 3.641

8.  Emergency vaccination of rabies under limited resources -- combating or containing?

Authors:  Dirk Eisinger; Hans-Hermann Thulke; Thomas Selhorst; Thomas Müller
Journal:  BMC Infect Dis       Date:  2005-03-07       Impact factor: 3.090

9.  Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab).

Authors:  Beatriz P Quiambao; Hazel Z Dytioco; Ruby M Dizon; Marilyn E Crisostomo; Thelma M Laot; Dirk E Teuwen
Journal:  PLoS Negl Trop Dis       Date:  2008-05-28

10.  Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis.

Authors:  Paola De Benedictis; Andrea Minola; Elena Rota Nodari; Roberta Aiello; Barbara Zecchin; Angela Salomoni; Mathilde Foglierini; Gloria Agatic; Fabrizia Vanzetta; Rachel Lavenir; Anthony Lepelletier; Emma Bentley; Robin Weiss; Giovanni Cattoli; Ilaria Capua; Federica Sallusto; Edward Wright; Antonio Lanzavecchia; Hervé Bourhy; Davide Corti
Journal:  EMBO Mol Med       Date:  2016-04-01       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.